Funding profile · Infectious disease diagnostics

Astek Diagnostics

Six Form D offerings since 2020 account for $4.15 million of equity sold, against a company-reported total of $7.6 million. Three NSF awards supply most of the rest. A $15 million round was still being raised in early 2025.

$4.15MEquity sold across six Form D offerings, 2020 to 2025
$1.54MNSF SBIR awards, 27% of the money on record
$7.6MTotal raised, company-reported, September 2024
$15MRound the company has said it is raising since 2024

Data as of September 22, 2026. Company-reported figures are labeled.

Rounds at a glance

When Round Amount Investors Source
Jun 2020 First sale, filed Aug 2023 $150,000 sold of $150,000 1 investor. TEDCO reported a $150,000 formation investment that year Form D
Jul 2021 First sale, filed Aug 2023 $345,000 sold of $345,000 10 investors. Y Combinator Summer 2021 batch Form D
Dec 2022 First sale, filed Aug 2023 $350,000 sold of $350,000 2 investors Form D
Mar to Aug 2023 Seed, twice amended $1,405,000 sold of $2,000,000 11 investors. Reported as a $2M close led by Wexford SciTech Venture Fund with Iyana Capital, Maryland Momentum Fund and TEDCO Form D and reporting
Oct 2023 Pre-Series A $1,150,000 sold of $2,500,000 at filing 4 investors. Reported as a $1.4M pre-Series A in Nov 2023; She’s Independent led in March 2024 Form D and reporting
Apr 2025 Latest filed offering $750,000 sold of $1,500,000 2 investors Form D
Jun 2025 TEDCO dual investment $500,000 TEDCO Pre-Seed Builder and Venture Funds State agency
Aug 2026 Seed, announced $750,000 TEDCO Seed Funds and Life Science Investment Fund Trade press
2021 to 2026 Federal grants $1,542,394 NSF SBIR Phase I twice and Phase II NSF

What the filings show

Astek Diagnostics, Inc. · Form D · filed Apr 28, 2025

First sale
Apr 4, 2025
Offered
$1,500,000
Sold
$750,000 · $750,000 remaining
Investors
2 · average $375,000
Exemption
Rule 506(b)
Related persons
Mustafa Al-Adhami (executive officer, director)
Filing
SEC EDGAR, CIK 0001972498, Halethorpe, MD

Astek Diagnostics, Inc. · Form D · filed Oct 19, 2023

First sale
Oct 1, 2023
Offered
$2,500,000
Sold
$1,150,000 · $1,350,000 remaining
Investors
4 · average $287,500
Exemption
Rule 506(b)
Related persons
Mustafa Al-Adhami (executive officer)
Filing
SEC EDGAR, accession 0001972498-23-000007

Astek Diagnostics, Inc. · Form D and two amendments · filed Apr 5, Jun 8 and Aug 28, 2023

First sale
Mar 22, 2023
Offered
$2,000,000
Sold
$1,000,000 at filing, $1,155,000 in June, $1,405,000 in August
Investors
6, then 10, then 11 · average about $127,700 at the last count
Exemption
Rule 506(b)
Related persons
Mustafa Al-Adhami (executive officer, director)
Filing
SEC EDGAR, accessions 0001972498-23-000001, -000002, -000003

Astek Diagnostics, Inc. · three catch-up Form D notices · all filed Aug 28, 2023

First sales
Jun 16, 2020; Jul 30, 2021; Dec 22, 2022
Sold
$150,000; $345,000; $350,000, each in full
Investors
1; 10; 2 · averages $150,000, $34,500, $175,000
Exemption
Rule 506(b) in each
Year of incorporation
2021, on all three
Filing
SEC EDGAR, accessions 0001972498-23-000004, -000005, -000006

Reading the filings

  1. Three years of financings were filed on a single day.On August 28, 2023 the company filed three Form D notices covering first sales of June 16, 2020, July 30, 2021 and December 22, 2022, plus an amendment to the live 2023 offering. A Form D is due within 15 days of the first sale, so the 2020 notice arrived more than three years late. The company registered with the SEC in 2023, and the catch-up reads as a cleanup of the file.
  2. The first sale predates the stated incorporation year.All three catch-up notices give 2021 as the year of incorporation, while one reports a first sale on June 16, 2020. The NSF awardee of record is Astek Diagnostics LLC; the SEC issuer is Astek Diagnostics, Inc.
  3. Checks got larger as the story got later.Average investment per investor runs $34,500 in the 2021 notice, about $127,700 in the twice amended 2023 offering, $287,500 in October 2023 and $375,000 in April 2025. Ten small angels at the start, two institutional size checks at the end.
  4. Announced money runs ahead of filed money.Form D notices account for $4.15M sold. The company told a trade outlet in September 2024 that it had raised $7.6 million, and a university profile lists $5.3M invested plus $2.3M in grants, of which $1,542,394 is visible in NSF records. Securities sold under Section 4(a)(2) generate no Form D, so the gap is not evidence of anything improper.
  5. The 2026 round has no Form D yet.TEDCO was announced in August 2026 as leading a $750,000 seed round. The last EDGAR filing, April 28, 2025, reports the same $750,000 sold to two investors. Either the announcement describes money already filed, or a notice is outstanding.
  6. The target moved in public.A September 2024 trade article carries a correction: “The company has clarified that it is raising $15 million rather than the $25 million it had initially told 360Dx.” The $15 million figure was repeated in February 2025, with a term sheet described as being finalized. No round of that size appears in the filings.

Commercial signals

Signal Detail Source type
Regulatory No FDA clearance. Pre-submission completed Oct 2024, De Novo planned for catheter associated UTI. Public record
Clinical evidence One peer reviewed study, PLoS One, Feb 2026, 289 samples, company funded, infection biomarker only. No registered trials. Public record
Demand Early access letters of intent from MedStar Health and urology practices; $30 million of first year revenue forecast after clearance. Company-stated
Unit economics Analyzer at cost near $6,500, cartridges about $50, reimbursement sought at $100 to $250. Trade press
Competition Sysmex Astrego PA-100 reports bacteriuria in 15 minutes and susceptibility in 45 in a published evaluation. Pattern Bioscience won FDA breakthrough designation for a urine panel in September 2026. Independent

What to watch

  • A Form D covering the round announced in August 2026, or an amendment filling the April 2025 offering.
  • Any filing consistent with the $15 million raise.
  • Whether grant income replaces equity once the NSF Phase II award ends on August 31, 2026.
  • Board composition after the September 2026 appointment of an executive chairman. Filings list one related person, the founder.

The Astek Diagnostics story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Scanwell Health: Also in Diagnostics. A Los Angeles company that turned a phone camera into a urinalysis reader and sold the first over-the-counter urine testing app in the United States
  • Zergo: Also in Diagnostics. A Waterloo nanotechnology team built a cannabis breathalyzer, then pointed the same electrochemical sensor at fertility hormones in urine
  • Moichor: Also in Diagnostics. An AI-assisted animal blood and cytology lab that started with birds and reptiles and now sells an in-clinic analyzer for dogs and cats
  • Lucira Health: Also in Diagnostics. The first fully at home COVID test, then the first at home flu test

Sources

  1. Public recordForm D and Form D/A filings, Astek Diagnostics, Inc., CIK 0001972498SEC EDGAR · Apr 5, 2023 to Apr 28, 2025
  2. Public recordNSF awards 2136428, 2304069 and 2423587NSF and SBIR.gov · 2021 to 2026
  3. State agencyTEDCO Invests in Astek DiagnosticsTEDCO · Jun 17, 2025
  4. State agencyBaltimore biotech company works to protect women’s healthMaryland Department of Commerce · Apr 4, 2025
  5. IndependentStartup Astek Dx Aims to Deliver One-Hour UTI Testing With Optical Test System360Dx, Greg Cima · Sep 27, 2024
  6. IndependentAstek Diagnostics raises $750K seed to speed up antibiotic testingDealroom News · Aug 25, 2026
  7. IndependentMoney Moves: Astek Diagnostics raised $2M for a medical device launchTechnical.ly · Jun 12, 2023
  8. CompanyAstek Diagnostics Appoints Doug White as Executive ChairmanEIN Presswire · Sep 21, 2026

Compiled from SEC, NSF, USPTO and other public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Astek Diagnostics. This page is not an offer to sell or a recommendation to buy any security.